BTK抑制剂-话题@MedSci

#BTK抑制剂#

60篇内容 | 3443人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1297378, encodeId=985f129e37873, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=BTK抑制剂盐酸Tirabrutinib（ONO-4059）治疗复发难治原发性中枢神经系统淋巴瘤, objectType=article, longId=178358, objectId=fc601e83580d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc601e83580d, replyNumber=0, likeNumber=72, createdTime=2019-08-31, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc601e83580d, moduleTitle=BTK抑制剂盐酸Tirabrutinib（ONO-4059）治疗复发难治原发性中枢神经系统淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc601e83580d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297377, encodeId=62ce129e37730, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查, objectType=article, longId=178216, objectId=e9211e8216cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9211e8216cb, replyNumber=0, likeNumber=73, createdTime=2019-08-28, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9211e8216cb, moduleTitle=百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9211e8216cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297376, encodeId=018e129e37602, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, objectType=article, longId=177713, objectId=d3701e7713cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3701e7713cf, replyNumber=0, likeNumber=67, createdTime=2019-08-17, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3701e7713cf, moduleTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3701e7713cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297375, encodeId=fb81129e37572, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=阿斯利康的BTK抑制剂Calquence治疗白血病喜获美国突破疗法指定, objectType=article, longId=177712, objectId=28c91e77129a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c91e77129a, replyNumber=0, likeNumber=70, createdTime=2019-08-17, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c91e77129a, moduleTitle=阿斯利康的BTK抑制剂Calquence治疗白血病喜获美国突破疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28c91e77129a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297374, encodeId=449f129e3749d, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, objectType=article, longId=176194, objectId=46cc1e6194e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46cc1e6194e7, replyNumber=0, likeNumber=70, createdTime=2019-07-27, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46cc1e6194e7, moduleTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46cc1e6194e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297373, encodeId=7c81129e3736c, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=徐卫教授：泽布替尼在复发/难治CLL中疗效及安全性均优，有望成为“Best in-class”BTK抑制剂, objectType=article, longId=174323, objectId=556a1e4323e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556a1e4323e6, replyNumber=0, likeNumber=73, createdTime=2019-06-29, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556a1e4323e6, moduleTitle=徐卫教授：泽布替尼在复发/难治CLL中疗效及安全性均优，有望成为“Best in-class”BTK抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556a1e4323e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297372, encodeId=e71c129e372cd, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=NEJM：口服BTK抑制剂治疗多发性硬化, objectType=article, longId=168870, objectId=9b371688e02f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b371688e02f, replyNumber=0, likeNumber=63, createdTime=2019-06-22, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b371688e02f, moduleTitle=NEJM：口服BTK抑制剂治疗多发性硬化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b371688e02f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297371, encodeId=5756129e3715c, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期, objectType=article, longId=168704, objectId=32eb168e0473, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32eb168e0473, replyNumber=0, likeNumber=63, createdTime=2019-06-20, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32eb168e0473, moduleTitle=BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32eb168e0473)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297370, encodeId=89bc129e370cb, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=168695, objectId=da9416869531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9416869531, replyNumber=0, likeNumber=60, createdTime=2019-06-20, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9416869531, moduleTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9416869531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297369, encodeId=83bc129e36990, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据, objectType=article, longId=168608, objectId=f819168608ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f819168608ec, replyNumber=0, likeNumber=63, createdTime=2019-06-18, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f819168608ec, moduleTitle=第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f819168608ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297368, encodeId=dbcd129e3684f, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=BTK抑制剂ARQ 531的I期试验数据, objectType=article, longId=168606, objectId=a3671686067b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3671686067b, replyNumber=0, likeNumber=79, createdTime=2019-06-18, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3671686067b, moduleTitle=BTK抑制剂ARQ 531的I期试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3671686067b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297367, encodeId=b1e6129e36794, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破, objectType=article, longId=167336, objectId=20e616e33681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e616e33681, replyNumber=0, likeNumber=90, createdTime=2019-06-02, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e616e33681, moduleTitle=新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e616e33681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297366, encodeId=54a9129e3669f, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, objectType=article, longId=158889, objectId=58081588897d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58081588897d, replyNumber=0, likeNumber=78, createdTime=2019-01-27, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58081588897d, moduleTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58081588897d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297365, encodeId=2193129e365c2, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, objectType=article, longId=157138, objectId=55df15e138c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55df15e138c5, replyNumber=0, likeNumber=72, createdTime=2019-01-02, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55df15e138c5, moduleTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55df15e138c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297364, encodeId=180b129e364b7, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=淋巴瘤治疗：弯道超车的新一代BTK抑制剂到底好在哪？, objectType=article, longId=155355, objectId=117d155355bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117d155355bd, replyNumber=0, likeNumber=69, createdTime=2018-12-09, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117d155355bd, moduleTitle=淋巴瘤治疗：弯道超车的新一代BTK抑制剂到底好在哪？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117d155355bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297363, encodeId=218c129e36327, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=新一代BTK抑制剂Zanubrutinib具有多重优势, objectType=article, longId=154851, objectId=cf8715485131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf8715485131, replyNumber=0, likeNumber=73, createdTime=2018-12-02, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf8715485131, moduleTitle=新一代BTK抑制剂Zanubrutinib具有多重优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf8715485131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297362, encodeId=8400129e3628b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势, objectType=article, longId=154636, objectId=cc21154636ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc21154636ff, replyNumber=0, likeNumber=71, createdTime=2018-12-01, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc21154636ff, moduleTitle=朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc21154636ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297361, encodeId=9daf129e3618f, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天, objectType=article, longId=152201, objectId=c131152201af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c131152201af, replyNumber=0, likeNumber=67, createdTime=2018-10-31, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c131152201af, moduleTitle=【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c131152201af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297360, encodeId=f64e129e3600d, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=欧洲血液学杂志：TEC与BTK抑制剂出血副作用无关, objectType=article, longId=151581, objectId=71af15158109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71af15158109, replyNumber=0, likeNumber=67, createdTime=2018-10-24, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71af15158109, moduleTitle=欧洲血液学杂志：TEC与BTK抑制剂出血副作用无关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71af15158109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297359, encodeId=ab36129e35910, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性, objectType=article, longId=149438, objectId=e16114943801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e16114943801, replyNumber=0, likeNumber=80, createdTime=2018-09-25, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e16114943801, moduleTitle=CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e16114943801)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BTK抑制剂

2020-05-29

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

BTK抑制剂盐酸Tirabrutinib（ONO-4059）治疗复发难治原发性中枢神经系统淋巴瘤

2019-08-31

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查

2019-08-28

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症

2019-08-17

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

阿斯利康的BTK抑制剂Calquence治疗白血病喜获美国突破疗法指定

2019-08-17

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性

2019-07-27

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

徐卫教授：泽布替尼在复发/难治CLL中疗效及安全性均优，有望成为“Best in-class”BTK抑制剂

2019-06-29

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

NEJM：口服BTK抑制剂治疗多发性硬化

2019-06-22

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期

2019-06-20

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期

2019-06-20

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据

2019-06-18

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

BTK抑制剂ARQ 531的I期试验数据

2019-06-18

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破

2019-06-02

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验

2019-01-27

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择

2019-01-02

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

淋巴瘤治疗：弯道超车的新一代BTK抑制剂到底好在哪？

2018-12-09

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

新一代BTK抑制剂Zanubrutinib具有多重优势

2018-12-02

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势

2018-12-01

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天

2018-10-31

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

欧洲血液学杂志：TEC与BTK抑制剂出血副作用无关

2018-10-24

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性

2018-09-25

科室
- - 订阅+
  - 更多科室
工具
服务